Patent · US Active

PSMA targeted radiohalogenated urea-polyaminocarboxylates for cancer radiotherapy

US12233137B1 · kind B1 · utility

0Cited by

2References

20Claims

0Family size

Assignees

THE JOHNS HOPKINS UNIVERSITY · US
Duke University · US

Inventors

Martin G. Pomper · Baltimore, US
Ronnie C. Mease · Fairfax, US
Vivek Kumar · Delhi, IN
Sangeeta Ray · Ellicott City, US
Michael Zalutsky · Chapel Hill, US
Ganesan Vaidyanathan · Flanders, US

Key dates

Filing date	Aug 11, 2023
Grant date	Feb 25, 2025
Priority date	—
Expiry date	Aug 11, 2043

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC12Y304/17021
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Small molecule radiohalogenated PSMA inhibitors and metal complexes thereof and their use in radioimaging and radiotherapy for treating PSMA-related diseases, including prostate cancer, are disclosed. The combination of small molecule radiohalogenated PSMA inhibitors with a competitive PSMA ligand for reducing off-target accumulation of the radiohalogenated PSMA inhibitor also is disclosed.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.